Skip to search formSkip to main contentSkip to account menu

BT 563

Known as: BT-563, BT563 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

inolimomab

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2004
2004
Ten-year follow-up of recipients of a kidney or heart transplant who received induction therapy with a monoclonal antibody against the interleukin-2 receptor.
2003
2003
Anti-CD25 antibody (BASILIXIMAB) therapy is not superior to anti-thymocyte globuline (ATG) for immunosuppression induction following heart transplantation
1998
1998
Blockade of the interleukin (IL)-2/IL-2 receptor pathway with a monoclonal anti-IL-2 receptor antibody (BT563) does not prevent the development of acute heart allograft rejection in humans.
BACKGROUND Anti-interleukin (IL)-2 receptor (IL-2R) antibodies have been used as rejection prophylaxis after organ… 
1998
1998
Anti-IL-2 receptor BT563 versus placebo: a randomized trial for induction therapy after liver transplantation.
1998
1998
Redundancy of the cytokine network in the development of rejection after clinical heart transplantation
Abstract We used reverse transcriptase–polymerase chain reaction analysis to study the effects of anti-rejection prophylaxis with… 
1996
1996
A randomized trial comparing safety and efficacy of OKT3 and a monoclonal anti-interleukin-2 receptor antibody (BT563) in the prevention of acute rejection after heart transplantation.
In a prospective randomized trial, BT563, a murine IgG, anti-interleukin-2 receptor antibody, was compared with OKT3 for use as… 
1996
1996
Influence of the anti-CD25 monoclonal antibody BT563 on clinical and biological rejection after orthotopic liver transplantation.
Highly Cited
1995
Highly Cited
1995
TREATMENT OF ACUTE GRAFT‐VERSUS-HOST DISEASE WITH METHYLPREDNISOLONE AND CYCLOSPORINE WITH OR WITHOUT AN ANTI‐INTERLEUKIN-2 RECEPTOR MONOCLONAL ANTIBODY: A Multicenter Phase III Study
A double-blind, placebo-controlled trial of BT563, including 13 European centers, was initiated in October 1989 to compare the… 
1995
1995
Pharmacodynamics of prophylactic antirej ection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation
1995
1995
Pharmacodynamics of prophylactic antirejection therapy with an anti interleukin-2 receptor monoclonal antibody (BT563) after heart and kidney transplantation.
A mouse monoclonal antibody (BT563) directed to the alpha-chain of the IL-2 receptor was administrated immediately after… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)